Thermo Fisher Scientific (TMO) stock price, revenue, and financials

Thermo Fisher Scientific market cap is $214.7 b, and annual revenue was $39.21 b in FY 2021

$214.7 B

TMO Mkt cap, 24-Jun-2022

$11.8 B

Thermo Fisher Scientific Revenue Q1, 2022
Thermo Fisher Scientific Gross profit (Q1, 2022)5.5 B
Thermo Fisher Scientific Gross profit margin (Q1, 2022), %46.2%
Thermo Fisher Scientific Net income (Q1, 2022)2.2 B
Thermo Fisher Scientific EBIT (Q1, 2022)2.8 B
Thermo Fisher Scientific Cash, 02-Apr-20222.8 B
Thermo Fisher Scientific EV245.2 B
Get notified regarding key financial metrics and revenue changes at Thermo Fisher ScientificLearn more
Banner background

Thermo Fisher Scientific Revenue

Thermo Fisher Scientific revenue was $39.21 b in FY, 2021 which is a 21.7% year over year increase from the previous period.

Embed Graph

Thermo Fisher Scientific Revenue Breakdown

Embed Graph

Thermo Fisher Scientific revenue breakdown by business segment: 37.0% from Life Sciences Solutions, 14.4% from Analytical Instruments, 13.4% from Specialty Diagnostics and 35.2% from Laboratory Products and Services

Thermo Fisher Scientific revenue breakdown by geographic segment: 8.8% from China, 48.2% from United States and 43.0% from Other

Thermo Fisher Scientific Income Statement

Annual

USDFY, 2019FY, 2020FY, 2021

Revenue

25.5b32.2b39.2b

Revenue growth, %

5%26%22%

Cost of goods sold

14.2b16.2b19.6b

Gross profit

11.3b16.0b19.6b

Gross profit Margin, %

44%51%50%

R&D expense

1.0b1.2b1.4b

General and administrative expense

6.1b6.9b8.0b

Operating expense total

6.7b8.2b9.6b

EBIT

4.6b7.8b10.0b

EBIT margin, %

18%24%26%

Interest expense

676.0m553.0m536.0m

Interest income

224.0m65.0m43.0m

Pre tax profit

4.1b7.2b8.8b

Income tax expense

374.0m850.0m1.1b

Net Income

3.7b6.4b7.7b

EPS

9.216.019.5

Thermo Fisher Scientific Balance Sheet

Annual

USDFY, 2019FY, 2020FY, 2021

Cash

2.4b10.3b4.5b

Accounts Receivable

4.3b5.7b8.0b

Inventories

3.4b4.0b5.1b

Current Assets

11.9b22.0b20.1b

PP&E

4.7b5.9b8.3b

Goodwill

25.7b26.0b41.9b

Total Assets

58.4b69.1b95.1b

Accounts Payable

1.9b2.2b2.9b

Short-term debt

676.0m2.6b2.5b

Current Liabilities

6.2b10.3b13.4b

Long-term debt

17.1b19.1b32.3b

Total Debt

17.8b21.7b34.9b

Total Liabilities

28.7b34.5b54.1b

Common Stock

434.0m437.0m439.0m

Additional Paid-in Capital

15.1b15.6b16.2b

Retained Earnings

22.1b28.1b35.4b

Total Equity

29.7b34.5b40.9b

Debt to Equity Ratio

0.6 x0.6 x0.9 x

Debt to Assets Ratio

0.3 x0.3 x0.4 x

Financial Leverage

2 x2 x2.3 x

Thermo Fisher Scientific Cash Flow

Annual

USDFY, 2019FY, 2020FY, 2021

Net Income

3.7b6.4b7.7b

Depreciation and Amortization

2.3b2.3b2.6b

Accounts Receivable

(225.0m)(1.3b)(204.0m)

Inventories

(458.0m)(508.0m)(1.1b)

Accounts Payable

266.0m59.0m479.0m

Cash From Operating Activities

5.0b8.3b9.3b

Purchases of PP&E

(926.0m)(1.5b)(2.5b)

Cash From Investing Activities

(1.5b)(1.5b)(21.9b)

Long-term Borrowings

(9.8b)(1.1b)(11.7b)

Dividends Paid

(297.0m)(337.0m)(395.0m)

Cash From Financing Activities

(3.1b)959.0m6.6b

Net Change in Cash

305.0m7.9b(5.8b)

Interest Paid

790.0m471.0m555.0m

Income Taxes Paid

896.0m1.3b2.2b

Thermo Fisher Scientific Ratios

USDFY, 2019

EV/EBIT

31.7 x

EV/CFO

29.3 x

Revenue/Employee

340.6k

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

2 x

P/E Ratio

35.4

Thermo Fisher Scientific Operating Metrics

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2020. Thermo Fisher Scientific's Backlog was reported to be $7.8b in FY, 2019.
FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020FY, 2020Q1, 2021Q2, 2021Q3, 2021FY, 2021

Customers

400 k400 k400 k

Remaining Performance Obligations

$5.09 b$5.57 b$7.07 b$6.76 b$7.77 b$8.36 b$9.99 b$11.16 b$12.81 b$13.29 b$13.56 b$14.49 b$28.3 b

Backlog

$5.09 b$7.77 b

Backlog (Life Sciences Solutions)

$647 m$893 m

Backlog (Analytical Instruments)

$2.24 b$2.2 b

Backlog (Specialty Diagnostics)

$187 m$172 m

Backlog (Laboratory Products and Services)

$2.06 b$4.58 b

Thermo Fisher Scientific Human Capital

Gender

FY, 2020FY, 2019
Female, percent10.1%40.4%
Male (Leadership, USA), percent15.8%
Male, percent14.4%58.8%
Female (Leadership, USA), percent9.3%
Female (Executive Management, USA), percent7.5%
Male (USA), percent14.7%
Female (USA), percent10.3%
Male (Executive Management, USA), percent17.5%
Other0.6%0.8%

Ethnicity

FY, 2020
Other Ethnicity (USA), percent21.2%
Other Ethnicity (Leadership, USA), percent24.8%
Ethnic Minorities (Executive Management, USA), percent7.4%
People of Color (USA), percent12.1%
People of Color (Leadership, USA), percent8.5%
Ethnic Non-Minorities (Executive Management, USA), percent26%

Thermo Fisher Scientific Employee Rating

3.87136 votes
Culture & Values
3.5
Work/Life Balance
3.3
Senior Management
3.1
Salary & Benefits
3.4
Career Opportunities
3.4
Source